Seattle Genetics Inc., of Bothell, Wash., said the FDA accepted for filing a supplemental BLA for Adcetris (brentuximab vedotin) in combination with chemotherapy for the front-line treatment of patients with advanced classical Hodgkin's lymphoma (HL).